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Abstract
Background: Chlamydial infection is a common bacterial sexually transmitted infection worldwide, caused by C.
trachomatis. The screening for C. trachomatis has been proven to be successful. However, such success is not fully
realized through tailoring the recommended screening strategies for different age groups. This is partly due to the
knowledge gap in understanding how the infection is correlated with age. In this paper, we estimate age-dependent
risks of acquiring C. trachomatis by adolescent women via unprotected heterosexual acts.
Methods: We develop a time-varying Markov state-transition model and compute the incidences of chlamydial
infection at discrete age points by simulating the state-transition model with candidate per-encounter acquisition
risks and sampled numbers of unit-time unprotected coital events at different age points. We solve an optimization
problem to identify the age-dependent estimates that offer the closest matches to the observed infection incidences.
We also investigate the impact of antimicrobial treatment effectiveness on the parameter estimates and the differences
between the acquisition risks for the first-time infections and repeated infections.
Results: Our case study supports the beliefs that age is an inverse predictor of C. trachomatis transmission and that
protective immunity developed after initial infection is only partial.
Conclusions: Our modeling method offers a flexible and expandable platform for investigating STI transmission.
Keywords: Chlamydial infection, Acquisition risk, Transmission probability, Parameter estimation, State transition model

Background
Chlamydial infection, caused by the bacterium, C. trachomatis, is a commonly reported sexually transmitted infection (STI) worldwide [1]. It can be accurately diagnosed
and effectively cured if being treated promptly [2-4]. On
the other hand, the infection may go unnoticed for many
years and consequently lead to severe morbidities, including pelvic inflammatory disease, ectopic pregnancy, tubal
pregnancy, preterm birth, and increased susceptibility of
HIV infection [5-13]. Therefore, it is important to the
high-risk individuals and social groups as well as societies
in general to schedule screening tests at the right time.
The above clinical facts promote the model-based
analysis of screening programs for chlamydial infections
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[14-19]. Based on the evidence of high C. trachomatis
prevalence among adolescents and remaining risk for
repeated infection among those who were recently treated
for infection [20-27], routine population screening for
female adolescents, especially those who were recently
infected, has been suggested to be cost-effective, and
in some cases, cost-saving [18,28-31]. At present, some
routine screening strategies are endorsed by clinical
practice guidelines [32-34] and recommended to adolescents during their health visits [5,35,36]. However, when
tailoring such strategies (e.g., specifying the screening
frequency) with respect to age and prior infection status,
we face the challenge of lacking reliable epidemiological
data. Understanding the acquisition risk differences with
respect to age and prior infection status may offer insights
into the mechanism of C. trachomatis acquisition and
chlamydial infection. Such understanding will lead to
more detailed model-based economic studies on the
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effectiveness and cost-effectiveness of screening strategies,
which has the potential to further improve the prevention
of chlamydial infection.
In this paper, we use observational infection data to
estimate age-dependent per-encounter C. trachomatis
acquisition risks, i.e., the probability that a female subject
is infected with C. trachomatis through an unprotected
coital event. For brevity, we use acquisition risk for referring to per-encounter C. trachomatis acquisition risk. It is
unethical to design controlled experiments that expose
human subjects to infectious pathogens. This challenge is
alleviated with observational studies and model-based
studies. Katz [37] and Tu et al. [38] used cross-sectional
data and longitudinal data to estimate the acquisition risk,
respectively. The estimation was also described in several
model-based studies for screening program/strategy
evaluation. Kretzschmar et al. [14] developed an individualbased stochastic simulation model to describe the spread of
C. trachomatis in a heterosexual population with a highly
sexually active core group. The authors used Monte-Carlo
simulation to estimate the daily transmission rates. The
data source used in this paper for sexual behavior and
partnerships were based on a survey conducted in the
Netherlands in 1989 [39]. Kretzschmar et al. [15] used the
simulation model in [14], acquired the per partnership
transmission probability from [40], and applied the method
in [37] to estimate the per-act transmission probability.
Turner [17] used a more comprehensive stochastic network model based on Ghani et al. [41] for the estimation.
The network includes not only disease transmission and
recovery but also dynamic partnership choice, formation,
and dissolution. The transmission probabilities per sex act
were estimated by systematic fitting to a variety of appropriate UK-based data sources [42,43]. Other studies on
the transmissibility of C. trachomatis include Gray et al.
[44], Lycke et al. [45], Ruijs et al. [46], and Vickerman
et al. [47]. However, none of the papers above investigated
the age- and prior-infection-dependency on C. trachomatis
transmissibility. Additionally, many model-based studies
used multiple data sources and relied on expert opinion
driven model assumptions. For a list of works on estimating
or using C. trachomatis transmission probabilities, we refer
to Additional file 1.
To estimate age-dependent acquisition risks, we developed a Markov-based individual state-transition model that
describes the changes in states of infection for each subject
over time. The transition probabilities in the model are
time-varying. In addition, we extended our model to investigate the difference on the acquisition risk that leads
to a first-time infection and leads to a repeated infection.
Furthermore, we varied the effectiveness of antimicrobial
treatment to assess its impact on the acquisition risk
estimates. Methodologically, the approach proposed is
a novel application of time-varying Markov modeling
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with longitudinally observed infection data. It allows
us to assess the probability of failures in antimicrobial
treatment. To our knowledge, only Tu et al. [38] applied a
similar approach of using longitudinal data to estimate the
transmissibility of C. trachomatis. However, they did not
consider the potential age-dependency in the changes on
the infection state nor differentiate first-time infection and
repeated infection. While there are many articles estimating
the transmissibility of HIV/AIDS (e.g. [48,49]), few statistical approaches (e.g. [38]) were developed for bacterial
STI with additional data and methodological challenges.
Unlike HIV/AIDS, infections with STI bacteria are routinely treated and effectively cured. This causes a shift in
the state of infection and poses greater methodological
challenges on quantifying the transmissibility. Meanwhile,
frequently measured infection data are needed to capture
such infection dynamics. To our knowledge, few studies
have been designed to collect such data. In the next section,
we describe an observational study providing ideal data for
our research.
The acquisition risk is a population-specific quantity,
which reflects not only the transmissibility of the C.
trachomatis organism but also the organism’s prevalence
in the male partner population. Clearly, higher acquisition risks are associated with the organism being more
transmissible and being more prevalent among male
partners. Given C. trachomatis prevalence in the male partner population, one can quantify the male-to-female C.
trachomatis transmission probability for young women
within a particular age group to be the ratio between
the per-encounter C. trachomatis acquisition risk
within the particular age group and the prevalence among
the male partners that are associated with the young
women of that age group, i.e., per-encounter C. trachomatis
acquisition risk = transmission probability × prevalence in
the male partner population. For our case study, we used
the observational data on recurrent sexually transmitted
disease among the recruited adolescent women. Because
the exact prevalence of C. trachomatis infection in the male
partner population was not attained in the study used, we
in this paper focus on the estimation of acquisition risks,
which reflects the transmission risk presented in the male
partner population.
The remainder of the paper is organized as follows. In
Section 2, we describe the observational data set used in
the parameter estimation. In Section 3, we describe our
estimation method. In Section 4, we report our estimates
based on the data set and discuss the results. We draw
conclusions, discuss limitations, and outline future research
in Section 5.
Description of the analyzed data set

The observational data used in our case study were
collected through the “Young Women’s Project” (YWP),
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which is an epidemiological study of recurrent STI in adolescent women recruited from an inner city population
that was at increased risk of STI. The YWP started its enrollment in 1999. Its study design and data collection provide a platform for the estimation of the C. trachomatis
transmissibility. We present the data collection scheme in
Figure 1.
In a nutshell, young women between the ages of 14
and 17 years old were identified and recruited by the
project. The recruitment criteria used included 1) understanding English; 2) no serious mental or psychiatric
health problems; and 3) visiting one of three participating
primary care clinics. For those young women who met all
the recruitment criteria, they would be approached by
research staff and asked for enrollment. Note that these criteria do not depend on subjects’ prior sexual experience,
which ensures the randomness of the cohort. To enroll an
YWP study subject, she received initial interviews and
underwent a pelvic examination, during which a cervical
swab for STI testing was collected and analyzed with
nucleic acid amplification test for C. trachomatis. Infected participants were treated while at the clinics or
shortly after the test results became available. Enrolled
participants were then asked to visit their clinics on a
quarterly basis. At each follow-up visit during the study
period, enrolled participants underwent STI testing and
treatment. Also at each follow-up visit, the participants
received follow-up interviews, in which they were queried about the number of unprotected coital events since
previous visit. Most of the participations did not visit
the clinic every quarter and left the project before its
completion.
For our analysis, we collected 1173 quarterly test results
from the first 200 participants who were never infected
and have completed at least two follow-up visits. Their
average enrollment age was 15 years with standard deviation of 1.1 years. These participants underwent averagely
5.86 visits, ranging from 2 to 18. They stayed in the
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project for 8.2 years maximally and 3.2 years on average.
They reported averagely 14.3 quarterly unprotected coital events. C. trachomatis was detected from 208 of the
quarterly swab samples, equivalent to 17%. For more
information on the YWP data collection and the observational data set analyzed for this paper, we refer to
Tu et al. [38].
Description of the estimation method

For the estimation, we first developed an age-dependent
Markov state-transition model that depicts the disease
condition dynamics for each female individual (Figure 2).
In the model, we let C and I be the states where a female
subject does not and does have C. trachomatis, respectively. Without loss of generality, we assume that the age
range we study is [T1, T2]. We also assume Δt to be the
unit-time interval during which no state transition occurs
and all transition rates remain the same. With the YWP,
the smallest length for Δt is set to be a quarter year, the
time interval between two consecutive visits. Given the
studied age range [T1, T2] and the unit-time interval Δt, we
index the discrete age points to be i = 0, 1, ⌈(T2 ‐ T1)/Δt⌉
with 0 indexing T1 and N ≡ ⌈(T2 − T1)/Δt⌉ indexing T2. We
denote pi to be a constant acquisition risk between discrete
age points i and i + 1 for i = 0, 1, …, N - 1. That is, when
a subject of age point i is at state C, we assume that the
subject follows a constant probability to transition to
state I with unprotected coital events between the two
consecutive age points. Once a subject is at state I at
age point i, the only reason she does not transition back
to state C at the next discrete time point is due to the
ineffectiveness of the antimicrobial treatment. We use q
to measure the treatment effectiveness with the assumption that this quantity is constant irrespective of the age.
That is, q is the probability that a subject transitions to
state C given she is currently at state I. Lastly, we denote
ten ≥ T1 and tex ≤ T2 to be the entry and exit ages of a
female subject, respectively. We can conveniently map

Figure 1 Data collection scheme for the YWP: the blue dots indicate the determination of the STI status at enrollment and all
subsequent quarterly visits; the light green dots indicate antimicrobial treatment of infected subjects at the visits; and the red dots
indicate face-to-face interviews in which subjects reveal the number of unprotected coital events.
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Figure 2 State transition diagram of the age-dependent Markov
model that captures the disease condition dynamics for
chlamydial infection and curing at discrete age point i = 0, 1, …,
N – 1.

the two age values to two age point indices between 0 to
N. We call them ia ≥ 0 and ib ≤ N.
Let si be the state of a female subject between age
point i and i + 1 with ia ≤ i < ib. Let ni be the number of
unprotected coital events with an infected partner during
the same period. Assuming that the probability that a
female subject acquires C. trachomatis is independent
between any two unprotected coital events, the transition
probabilities are presented as: Pr (si+1 = C | si = C) =
ð1−pi Þni , which means that to ensure no infection, the
subject does not acquire C. trachomatis in any of the
unprotected coital events during the period. Here we also
assume a female subject has zero probability of acquiring
C. trachomatis from a protected coital event. Note that
a similar idea can be found in Katz [37]. It is easy to
determine the other transition probabilities in the statetransition model.
We next developed a cubic spline model, based on the
longitudinal study in Tu et al. [38], to predict the number
of unprotected coital events with an infected partner
during the next quarter year at age t (in years). The model
is presented as:
(

)
N
X

3
nðt Þ ¼ exp β0 þ β1 t þ β2 t þ β3 t þ
ui ðt−k i Þþ
:
2

3

i¼1

A cubic spline model is a polynomial function that is
piecewise-defined and possesses smoothness of order 3.
For each discrete age point i = 0, 1,.., N-1, we can use its
corresponding age, denoted by ti, to calculate n(ti) and
specify ni. The expression (a)+ indicates the value of a is
kept when it is nonnegative and its value is set to be 0
when negative. Given the data availability, the model
shows good fit for the age range between years of 15 and
24.75. In the model, N indicates the number of knots
and is set to be 40. The parameters ki, termed knots,
indicate age points between 14.5 and 24.5. These knots
are the places in the model where the polynomial pieces
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connect. The parameters ui, together with the base function
β0 + β1t + β2t2 + β3t3, ensure that the estimates of the spline
model match the corresponding observations exactly at
those age points. We report the model parameter values
in Additional file 2.
As an extension to incorporate cohort variation on the
number of unprotected coital events, we assume the
intercept (i.e., the first term β0) of the cubic spline model
for each simulated subject to be normally distributed with
mean being the intercept from the original model and
standard deviation being a percentage of the mean. Once
the intercept was sampled for each simulated subject, we
adjusted the corresponding cubic spline model but kept
the values of the knots the same for all the subjects to
ensure the necessary correlation among different time
points. Thus the extended stochastic model is presented
as:
(

)
N
X

3
;
nðt Þ ¼ exp u0 þ β0 þ β1 t þ β2 t þ β3 t þ
ui ðt−k i Þþ
2

3

i¼1

where u0 follows a normal distribution as u0 ~ N(0, (ρ × β0)2)
with 0 < ρ ≤ 1.
To estimate age-dependent acquisition risks, we applied
a reverse engineering approach with real age-specific chlamydial infection incidences extracted from the observational data. For any candidate age-dependent acquisition
risk profile, we simulated the infection incidence given a
collection of hypothetical female subjects, each of which is
assigned a random enrollment age and a random exit age,
based on the same observational data. For each subject,
we also followed the stochastic model above to uniquely
determine for each hypothetical subject the number of
unprotected coital events in all discrete age points from
the simulated enrollment to the simulated exit. With
the simulation of each subject, we recorded the age
points within which each infection occurred to the
subject. Finally, we tallied the number of chlamydial
infections for the entire simulated cohort within each
age group.
We constructed an optimization problem to compute
the acquisition risks with which the simulated incidences
match the observed ones most closely. To present the
optimization problem, let us introduce additional mathematical notation. We use Ii to denote the observed percentage of infected in the studied cohort for age group i = 1,…,
N. We use K to denote the set that contains the indices of
the simulation runs. For each age group i, we collect all
hypothetical subjects that experienced i during their enrollment (i.e., the age corresponding to i is between the
subject’s entry and exit ages). We denote K(i) ⊆ K to be the
subset that contains the simulation run indices for such
subjects. For each simulation run k ∈ K(i), we use Ii(k) ∈
{0, 1} to indicate whether an infection occurs for age
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group i = 1,…,N. The objective of the optimization
problem
is to minimize the difference between
X
1
I
ð
k
Þ , the simulated percentage of infected, and
i
j K ði Þj
k∈K ðiÞ

Ii for each i = 1,…,N. The optimal solution specifies
the age-dependent acquisition risk, which is denoted
 ¼ ðp
 1 ; …; p
 N Þ.
by p
We next considered the case where we distinguish the
acquisition risks for first-time infection and repeated
infection. This distinction is supported by the existing
literature. Many studies, mostly involving women, have
evaluated the risk of repeated infections during a period
of observation and found that repeated infections are
common during the first half a year after initially treated
infections [21,22]. Some of these studies [25,26] also
observed higher risk of repeated infections among younger
women. We therefore extended the above Markov statetransition model (Figure 3). We let C1 and C2 be the states
where a female subject is cured from chlamydial infection
for the first time and reinfection, respectively, due to
unprotected coital events. Similar to the first model, we
assumed that both risks are independent between any two
unprotected coital events. We denote p1t and p2t to be the
two corresponding acquisition risks, and denote n1t and
n2t to be the numbers of unprotected coital events before the first infection and after, respectively. Then we

n1
have Pr (si+1 = I | si = C1) = 1− 1−p1t t and Pr (si+1 = I |

n1

n2
si = C2) = 1− 1−p1t t 1− 1−p2t t . Once a subject has
been infected, she will only transition between C2 and I,
and never transition back to the state C1.
To estimate age-dependent acquisition risks, we again
applied a reverse engineering approach. We constructed
two optimization problems to compute the acquisition
risks that lead to first-time infection and reinfection.
With the acquisition risks, the simulated incidences (i.e.,
first-time infection incidence and reinfection incidence)
should match the observed ones most closely. To present
the optimization problems, let us introduce additional

Figure 3 State transition diagram of the time-varying Markov
model that captures the disease dynamics with first-time
chlamydial infection, curing, and repeated infection. Note
that the risks of chlamydial infection for the first time and
repeated infection are different; and the sexual behaviors before
and after the first-time infection are different as well.
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f
r
mathematical notation. We use S i and S j , respectively,
to denote the observed percentages of first-time infection
and repeated infection in the studied cohort for age group
i, j = 1,…, N. Similar to the above definition of K(i), we
introduce Kf(i) and Kr(i). For each simulation run k, we
f
use S i ðk Þ and S rj ðk Þ, respectively, to indicate whether a
first-time infection and a repeated infection occurs
within each age group. The objectives of the two
X f
f
optimization problems are to minimize K f1ðiÞ
S i ðk Þ−S i

and

1
jK r ðiÞj

X
k∈K r ðiÞ

j

r
S ri ðiÞ−S i

j

k∈K f ðiÞ

f

for each i = 1,…,N and j = 1,…, Nr,

respectively. The optimal solutions specify the agedependent risks of acquiring C. trachomatis for the first
time and reacquiring the bacterium, which are denoted by


 r

r ¼ p
 f1 ; …; p
 fN f and p
 1 ; …; p
 rN r , respectively.
f ¼ p
p

Results
In our numerical study, we used observational data collected through the YWP on age-specific chlamydial infection rate for the first time since the previous visit, denoted
by CT rate (i), and age-specific cumulative CT infection
rate (including both first-time infection and repeated
infection), denoted by cum_CT_rate(i), for each age point
i. We also tallied the total number of visits made by subjects
at each age group, denoted by total_popu(i). For the first
Markov model, we have I i = CT_rate(i) × total_popu(i).
We considered the age range from 15 to 24.75 with 3
months as the length of the fixed unit-time interval. That
f
is, N = 40. For the second Markov model, we have S i =
r
(1 – cum_CT_rate(i)) × total_popu(i) and S i =
(cum_CT_rate(i) – CT_rate(i)) × total_popu(i). Due to
data scarcity on cum_CT_rate(i), we considered the
age range from 17 to 22 with 6 months as the length of
the fixed unit-time interval for the second model. That
is, N = 10. For both Markov models, we used the cubic
spline model described earlier to predict the number of
unprotected coital events within each 3-month interval
between age 15 and 25. We introduced randomness to
the cubic spline model by assuming a normal distribution on the intercept (i.e., the first term β0) of the
model and setting its standard deviation to be 10% of
the intercept based on expert opinion, i.e., ρ = 10%.
Then we drew a sample from the normal distribution in
each simulation run. In both models, we also varied q,
the antimicrobial treatment failure probability, to be 0%,
5%, or 10%. It is worth noting that the treatment failure probability may have significant variation among
individual patients and clinics. That motivated us to
conduct a sensitivity analysis. Lau and Qureshi [50] reported in a meta-analysis of randomized clinical trials
that the failure probabilities of using azithromycin and
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doxycycline, the antibiotic considered in the YWP, to treat
genital chlamydial infections were on average 3% and 2%,
respectively. The treatment failure probability in a realworld setting is less defined and difficult to measure. A recent article (Tu et al. [38]) suggested using 10% as the expected chance of a treatment failure. These numbers
helped us specify the probability range for our sensitivity
analysis.
We ran the simulation 10,000 times with generation of
10,000 hypothetical subjects for the study of each case
described above. We report in Tables 1 and 2 the means
at selected age points. From Table 1, we observed that 1)
 monotonically decreases as age increases; 2) p
 decreases
p
as q increases. The first observation supports the evidence
that the rate and prevalence of chlamydial infection are
shown inversely related with age [51,52]. The second observation matches the intuition behind the relationship
between treatment effectiveness and infection risk. If the
treatment is less effective, the infected individual stays
longer in state I and thus takes a longer period of time to
be infected again. This leads to a lower acquisition risk to
match the observational data. From Table 2, we observed
 r is positive; 2) both p
 f and p
 r monotonically decrease
1) p
r
 decreases as q increases. The
as age increases, and 3) p
first observation support the concept that some degree of
protective immunity against reinfection develops after
first-time infection, although it appears to be partial at
best [53,54]. The second observation supports the concept
that acquired protective immunity may restrict chlamydia
replication in older persons [55]. In other words, in
addition to likely inverse relationship between age and unprotected sexual activity, organism load has been shown
inversely related with age as well. As a result, many naive
persons, considering themselves treated for initial infections successfully, may resume sexual activity at a level as
active as before if not more active [22]. The third observation can be interpreted in the same way as earlier. Note
that first-time infection occurs prior to any treatment.
Hence, the estimate for the first-time infection is independent of the treatment effectiveness.
We also computed the standard deviations of the estimates over multiple simulation runs for both models. All
the standard deviations on the estimates over multiple
simulation runs are small relative to the mean estimates.
This implies that the cohort variation on the risk estimates
is nearly negligible when using 10% as the maximum
variation on the number of unprotected coital events.

We summarize the results in the following. First, our
estimates are comparable to those in the literature.
Based on the data collected from the same project, Tu
et al. [38] estimated the per-encounter acquisition risk
to be 0.009, which is between the estimates for 19 years
old and 20 years old in our study. We think this is reasonable, considering the average enrollment age is 15 and
average stay duration is 3.2 years. Kretzschmar et al. [15]
estimated the upper bound for the per-contact probability
of transmission to be 0.108 from male to female via casual
sex contacts without condom use. Considering an approximately 7.6% of chlamydia prevalence in the age group of
15–39 cited by the authors in [15], we reasoned that the
prevalence in the age group of 15 – 25 would be higher, approaching 10%. Then an upper bound on the acquisition
risk based on their estimate would have been approximately
0.01. See Additional file 1 for a list of transmissibility
estimates in the literature. Second, our results support
the well-established evidence that age is an inverse independent predictor of chlamydial infection [51]. One of
the most robust epidemiologic characteristics of chlamydial infection is higher prevalence among younger
persons than older ones [50]. The inverse relationship
between age and prevalence suggests that protective immunity is acquired over time. Third, our results support
the hypothesis that protective immunity is partial at best
[53]. Additional analysis with our data set also supported
the evidence that repeated infections were strongly related
with resumption of sexual activity [22], e.g., we found a
similar level of sexual activity was resumed shortly after
the treatment.

Discussion
In this paper, we proposed a Markov-based individual
state-transition model with age-varying transition probabilities to estimate age-specific risks of per-encounter C.
trachomatis acquisition. To calibrate the model, we solved
an optimization problem to identify the acquisition risks
with which the simulated infection incidences match the
observed ones at discrete age points. We conducted our
case studies based on the data collected in a longitudinal
study of recurrent STI among inter-city adolescent
women. We further extended the model to study the
differentiation between first-time infection and repeated
infection.
There are a few issues that could potentially limit the
use of the proposed method in practice. First, if an estimate

 ) (1st Model)
Table 1 Estimated risk of per-encounter C. trachomatis acquisition (p
Age (yrs)

15

16

17

18

19

20

21

22

23

24

p

q = 0%

0.0585

0.0352

0.0243

0.0168

0.0110

0.0074

0.0052

0.0039

0.0024

0.0016

q = 5%

0.0578

0.0344

0.0241

0.0167

0.0107

0.0072

0.0051

0.0034

0.0023

0.0015

q = 10%

0.0569

0.0342

0.0239

0.0164

0.0106

0.0071

0.0050

0.0032

0.0022

0.0014
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 f ) and repeated
Table 2 Estimated per-encounter acquisition risks of C. trachomatis causing first-time infection (p
r
 ) (2nd Model)
infection (p
Age (yrs)

17

17.5

18

18.5

19

19.5

20

20.5

21

21.5

p f

0.0266

0.0216

0.0193

0.0169

0.0142

0.0122

0.0100

0.0075

0.0059

0.0049

q = 0%

0.0211

0.0133

0.0093

0.0070

0.0049

0.0038

0.0032

0.0028

0.0023

0.0018

q = 5%

0.0185

0.0120

0.0086

0.0063

0.0045

0.0035

0.0029

0.0025

0.0021

0.0016

q = 10%

0.0159

0.0102

0.0072

0.0055

0.0126

0.0031

0.0024

0.0021

00018

0.0044

r
p

on C. trachomatis transmissibility is requested, one must
acquire knowledge on the prevalence of C. trachomatis
among the male partner population for each age-dependent
female population subgroup, which is essential to the
conversion of age-specific acquisition risk into the agespecific transmission probability. Even in latest observational studies, it remains challenging to acquire
accurate assessment on the C. trachomatis prevalence
for the entire male partner population especially for
the female cohort with extended casual sexual relationships. However, the proposed method provides a framework for “what-if” scenario analysis. Given hypothesized
prevalence data, one can easily calculate the age-specific
transmission probability and further conduct economic
analysis on preventive programs/strategies. Second, our
estimates are clearly affected by the accuracy of STI
testing and behavioral reporting. It is worth noting
that the researchers conducting the YWP undertook
rigorous laboratory procedures to ensure the former
accuracy. Meanwhile, Tu et al. [38] did not find much
reporting bias among the study subjects when comparing self-reported coital counts attained from interviews at quarterly visits with those from subjects’ daily
diaries in the same period. From a modeling point of
view, inaccuracy of STI testing can be incorporated in
the Markov state-transition model with updated transition
probabilities for Pr (si+1 = C | si = C) = ð1−pi Þni þ
ð1−ð1−pi Þni Þ  q0 where q ' is the false negative rate of
the testing. As for modeling of behavior misreporting,
since it is about the issue of mainly underreporting, a
multiplier between 0 and 1 can be added to n(t) for the
adjustment. Finally, we did not have data on the infection status of the sex partners of the study subjects. As
a result, we were unable to build a finer-grained stochastic network type model that incorporates various
aspects of inter-subject variations, e.g., we assumed a
constant probability of having an infected partner for
all sexual relationships. Ghani et al. [41] and Turner
et al. [17] provide decent references on realistic sexual
network models. Furthermore, it should be noted that
we did assume a normal distribution on the number of
sex acts among the study subjects. However, it was
difficult to verify this assumption. Furthermore, we
only varied the baseline for the subjects but did not

incorporate potential differences on the temporal
correlations of sex acts. A boarder class of distributions would be needed to protect the model from
misspecification.
Despite of these limitations, we present a flexible and
expandable platform for investigating various aspects of
bacterial STI transmission. In our future research, we
will address the aforementioned limitations with more
systematic study of chlamydial infection data and more
systematic analysis of realistic stochastic sexual network
models.
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